Israeli scientists are “excited” to discover that aspirin is shortening COVID illnesses to a couple of days and removing lingering after-effects.
Patients who take even small doses of aspirin are 29 percent less likely to test positive for the novel coronavirus, and those who do contract it experience reduced after-effects and generally recover faster,.
Milana Frenkel-Morgenstern from Bar-Ilan University said: “We were really excited to see a big reduction in the proportion of people testing positive, and this gives a promising indication that aspirin, such a well-known and inexpensive drug, may be helpful in fighting the pandemic.”
In the research, which was peer-reviewed, experts also determined that aspirin users who contract COVID-19 usually experience a shorter illness of roughly two days and suffer less after-effects or forms of ‘long Covid’.
Frenkel-Morgenstern said: “This finding with regard to long COVID, a phenomenon that is a real concern, is very important.”
The study looked at people who take small doses of aspirin, around 75 milligrams, to help prevent cardiovascular diseases without having such conditions. The results were then tweaked to take into account age and comorbidities.
The research has been published in The FEBS journal, a peer-reviewed biweekly scientific journal.
Lead author Professor Eli Magen said: “This observation of the possible beneficial effect of low doses of aspirin on COVID-19 infection is preliminary but seems very promising.”
Frenkel-Morgenstern added that it is currently unknown why aspirin apparently reduces the risk of infection, but she believes it shortens the virus’ lifespan due to its anti-inflammatory properties.
She pointed out that research is still early and hopes the report will prompt further study into the subject.
Frenkel-Morgenstern also added that she does not recommend that people start self-prescribing themselves aspirin.
The Ananova page is created by and dedicated to professional, independent freelance journalists. It is a place for us to showcase our work. When our news is sold to our media partners, we will include the link here.